The Circulating Proteome -Technological Developments, Current Challenges, and Future Trends

Product:

Inflammation Panel 250

Topic:

Technology

Disease Area:

Review

Sample Type:

Topic/Product:

Inflammation Panel 250

Disease Area:

Review

Sample Type:

Abstract

Recent improvements in proteomics technologies have fundamentally altered our capacities to characterize human biology. There is an ever-growing interest in using these novel methods for studying the circulating proteome, as blood offers an accessible window into human health. However, every methodological innovation and analytical progress calls for reassessing our existing approaches and routines to ensure that the new data will add value to the greater biomedical research community and avoid previous errors. As representatives of HUPO’s Human Plasma Proteome Project (HPPP), we present our 2024 survey of the current progress in our community, including the latest build of the Human Plasma Proteome PeptideAtlas that now comprises 4608 proteins detected in 113 data sets. We then discuss the updates of established proteomics methods, emerging technologies, and investigations of proteoforms, protein networks, extracellualr vesicles, circulating antibodies and microsamples. Finally, we provide a prospective view of using the current and emerging proteomics tools in studies of circulating proteins.

Authors & Affiliations

Philipp E. Geyer*, Daniel Hornburg, Maria Pernemalm, Stefanie M. Hauck, Krishnan K. Palaniappan, Vincent Albrecht, Laura F. Dagley, Robert L. Moritz, Xiaobo Yu, Fredrik Edfors, Yves Vandenbrouck, Johannes B. Mueller-Reif, Zhi Sun, Virginie Brun, Sara Ahadi, Gilbert S. Omenn, Eric W. Deutsch*, Jochen M. Schwenk*

Department of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O’Hara Street, Pittsburgh, PA 15213, USA
Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15213, USA
Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA
Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
Geriatric Research Education and Clinical Center, VA Pittsburgh HS, Pittsburgh, PA, USA
Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
*Corresponding author. Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh 15213, PA, USA.

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.